DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
PENTYLENETETRAZOL
2
Small molecule
Investigational
Unknown
Unknown
Idiopathic Hypersomnia; Respiratory Tract Diseases
Unknown
PENTYLENETETRAZOL
×
Maximum Phase:
2
First Approval:
None
UNII:
WM5Z385K7T
Molecule Type:
Small molecule
Molecular Formula:
C6H10N4
Molecular Weight:
138.17
AlogP:
0.4
PSA:
43.6
HBD:
0.0
HBA:
#RotB:
0.0
Source:
VABICASERIN HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Serotonin 2a (5-HT2a) receptor antagonist
VABICASERIN HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
2759C7222C
Molecule Type:
Small molecule
Molecular Formula:
C15H21ClN2
Molecular Weight:
264.8
AlogP:
2.49
PSA:
15.27
HBD:
1.0
HBA:
#RotB:
0.0
Source:
NIM811
2
Protein
Investigational
Unknown
Unknown
Hepatitis C, Chronic
Unknown
NIM811
×
Maximum Phase:
2
First Approval:
None
UNII:
96262S4I14
Molecule Type:
Protein
Molecular Formula:
C62H111N11O12
Molecular Weight:
1202.63
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
MAGNESIUM L-LACTATE DIHYDRATE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
MAGNESIUM L-LACTATE DIHYDRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EGAPTIVON PEGOL
2
Protein
Investigational
Unknown
Unknown
Thrombosis; Purpura, Thrombotic Thrombocytopenic; von Willebrand Diseases
von Willebrand factor inhibitor
EGAPTIVON PEGOL
×
Maximum Phase:
2
First Approval:
None
UNII:
DT0445S65M
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CONTEZOLID
2
Small molecule
Investigational
Unknown
Unknown
Bacterial Infections
Bacterial 70S ribosome inhibitor
CONTEZOLID
×
Maximum Phase:
2
First Approval:
None
UNII:
B669M62ELP
Molecule Type:
Small molecule
Molecular Formula:
C18H15F3N4O4
Molecular Weight:
408.34
AlogP:
2.82
PSA:
87.91
HBD:
1.0
HBA:
#RotB:
5.0
Source:
CODRITUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Hepatocellular
Glypican-3 inhibitor
CODRITUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
U9I0PLD4HT
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PONEZUMAB
2
Antibody
Investigational
Unknown
Unknown
Alzheimer Disease; Cerebral Amyloid Angiopathy
Beta amyloid A4 protein binding agent
PONEZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
1TG15H1XE9
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HYDROGEN
2
Unknown
Investigational
Unknown
Unknown
Glioma; Graft vs Host Disease; Parkinson Disease; Stroke
Unknown
HYDROGEN
×
Maximum Phase:
2
First Approval:
None
UNII:
7YNJ3PO35Z
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TRO-40303
2
Small molecule
Investigational
Unknown
Unknown
Myocardial Infarction
Unknown
TRO-40303
×
Maximum Phase:
2
First Approval:
None
UNII:
3W389841RN
Molecule Type:
Small molecule
Molecular Formula:
C26H47NO2
Molecular Weight:
405.67
AlogP:
6.91
PSA:
52.82
HBD:
2.0
HBA:
#RotB:
8.0
Source:
SARCNU
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Central Nervous System Neoplasms; Colorectal Neoplasms
Unknown
SARCNU
×
Maximum Phase:
2
First Approval:
None
UNII:
BHB013S3MO
Molecule Type:
Small molecule
Molecular Formula:
C6H11ClN4O3
Molecular Weight:
222.63
AlogP:
-0.25
PSA:
96.07
HBD:
1.0
HBA:
#RotB:
5.0
Source:
COSFROVIXIMAB
2
Antibody
Investigational
Unknown
Unknown
Hemorrhagic Fever, Ebola
Unknown
COSFROVIXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
820CI2BHRP
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MIPSAGARGIN
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Glioblastoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Sarcoplasmic/endoplasmic reticulum calcium ATPase inhibitor
MIPSAGARGIN
×
Maximum Phase:
2
First Approval:
None
UNII:
Q032I35QMX
Molecule Type:
Small molecule
Molecular Formula:
C66H100N6O27
Molecular Weight:
1409.54
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
GLPG-0259
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
MAP kinase-activated protein kinase 5 inhibitor
GLPG-0259
×
Maximum Phase:
2
First Approval:
None
UNII:
52EG7RFE6Y
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
APELIN
2
Unknown
Investigational
Unknown
Unknown
Diabetes Mellitus
Unknown
APELIN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DANUGLIPRON
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Diabetes Mellitus, Type 2; Obesity
Glucagon-like peptide 1 receptor agonist
DANUGLIPRON
×
Maximum Phase:
2
First Approval:
None
UNII:
DN9IUI24GP
Molecule Type:
Small molecule
Molecular Formula:
C31H30FN5O4
Molecular Weight:
555.61
AlogP:
4.89
PSA:
113.5
HBD:
1.0
HBA:
#RotB:
9.0
Source:
GSK-3174998
2
Unknown
Investigational
Unknown
Unknown
Multiple Myeloma; Neoplasms
Tumor necrosis factor receptor superfamily member 4 agonist
GSK-3174998
×
Maximum Phase:
2
First Approval:
None
UNII:
CT69TVL1KE
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
QUINAGOLIDE
2
Small molecule
Investigational
Unknown
Unknown
Ovarian Hyperstimulation Syndrome
Dopamine D2 receptor agonist
QUINAGOLIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
80Q9QWN15M
Molecule Type:
Small molecule
Molecular Formula:
C20H33N3O3S
Molecular Weight:
395.57
AlogP:
2.14
PSA:
72.88
HBD:
2.0
HBA:
#RotB:
7.0
Source:
PLITIDEPSIN
2
Small molecule
Investigational
Unknown
Unknown
Liposarcoma; Lymphoma; Primary Myelofibrosis; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Neoplasms; Severe Acute Respiratory Syndrome
Elongation factor 1-alpha 2 inhibitor
PLITIDEPSIN
×
Maximum Phase:
2
First Approval:
None
UNII:
Y76ID234HW
Molecule Type:
Small molecule
Molecular Formula:
C57H87N7O15
Molecular Weight:
1110.36
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
CD40 LIGAND
2
Unknown
Investigational
Unknown
Unknown
Melanoma
Tumor necrosis factor receptor superfamily member 5 agonist
CD40 LIGAND
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BGT-226
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Hamartoma Syndrome, Multiple; Neoplasms
PI3-kinase class I inhibitor
BGT-226
×
Maximum Phase:
2
First Approval:
None
UNII:
ZXE7F2GMJJ
Molecule Type:
Small molecule
Molecular Formula:
C28H25F3N6O2
Molecular Weight:
534.54
AlogP:
4.38
PSA:
77.21
HBD:
1.0
HBA:
#RotB:
4.0
Source:
LEFITOLIMOD
2
Unknown
Investigational
Unknown
Unknown
HIV Infections
Toll-like receptor 9 agonist
LEFITOLIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
6SO72A12FN
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
STRONTIUM-89
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
STRONTIUM-89
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SQUARIC ACID DIBUTYL ESTER
2
Small molecule
Investigational
Unknown
Unknown
Herpes Labialis
Unknown
SQUARIC ACID DIBUTYL ESTER
×
Maximum Phase:
2
First Approval:
None
UNII:
4RTO57VG65
Molecule Type:
Small molecule
Molecular Formula:
C12H18O4
Molecular Weight:
226.27
AlogP:
1.64
PSA:
52.6
HBD:
0.0
HBA:
#RotB:
8.0
Source:
ELEZANUMAB
2
Antibody
Investigational
Unknown
Unknown
Ischemic Stroke; Multiple Sclerosis; Spinal Cord Injuries
Repulsive guidance molecule A inhibitor
ELEZANUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
SK1LVT23A1
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ORG-34517
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism; Depressive Disorder; Depressive Disorder, Major
Glucocorticoid receptor antagonist
ORG-34517
×
Maximum Phase:
2
First Approval:
None
UNII:
17VAN37K4Y
Molecule Type:
Small molecule
Molecular Formula:
C28H30O4
Molecular Weight:
430.54
AlogP:
5.07
PSA:
55.76
HBD:
1.0
HBA:
#RotB:
1.0
Source:
IODOCARB
2
Small molecule
Investigational
Unknown
Unknown
Fatigue Syndrome, Chronic; Pulmonary Disease, Chronic Obstructive
Unknown
IODOCARB
×
Maximum Phase:
2
First Approval:
None
UNII:
603P14DHEB
Molecule Type:
Small molecule
Molecular Formula:
C8H12INO2
Molecular Weight:
281.09
AlogP:
1.91
PSA:
38.33
HBD:
1.0
HBA:
#RotB:
4.0
Source:
ENMD-2076
2
Small molecule
Investigational
Unknown
Unknown
Hematologic Neoplasms; Multiple Myeloma; Neoplasms; Adenocarcinoma, Clear Cell; Breast Neoplasms; Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma
Fibroblast growth factor receptor 3 inhibitor
ENMD-2076
×
Maximum Phase:
2
First Approval:
None
UNII:
J6U9WP10T7
Molecule Type:
Small molecule
Molecular Formula:
C21H25N7
Molecular Weight:
375.48
AlogP:
3.17
PSA:
72.97
HBD:
2.0
HBA:
#RotB:
5.0
Source:
BLU-5937
2
Unknown
Investigational
Unknown
Unknown
Cough
Unknown
BLU-5937
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AR-67
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Gliosarcoma; Myelodysplastic Syndromes
Unknown
AR-67
×
Maximum Phase:
2
First Approval:
None
UNII:
3YEA04NV6H
Molecule Type:
Small molecule
Molecular Formula:
C26H30N2O5Si
Molecular Weight:
478.62
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
VELUSETRAG
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Gastroparesis
Serotonin 4 (5-HT4) receptor agonist
VELUSETRAG
×
Maximum Phase:
2
First Approval:
None
UNII:
J4VNV64ARB
Molecule Type:
Small molecule
Molecular Formula:
C25H36N4O5S
Molecular Weight:
504.65
AlogP:
1.56
PSA:
111.95
HBD:
2.0
HBA:
#RotB:
8.0
Source:
DE-112
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DE-112
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AEZS-108
2
Protein
Investigational
Unknown
Unknown
Unknown
Unknown
AEZS-108
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IRL790
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
IRL790
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EVENAMIDE
2
Small molecule
Investigational
Unknown
Unknown
Schizophrenia
Sodium channel alpha subunit blocker
EVENAMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
ON5S6N53JS
Molecule Type:
Small molecule
Molecular Formula:
C16H26N2O2
Molecular Weight:
278.4
AlogP:
2.09
PSA:
41.57
HBD:
1.0
HBA:
#RotB:
9.0
Source:
1
2
…
201
202
203
204
205
206
207
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA